OmniAb, Inc. (OABIW) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は EmeryVille, CA, アメリカ. 現CEOは Matthew W. Foehr.
OABIW を有する IPO日 2021-09-30, 114 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $15.13M.
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
